home / stock / sonn / sonn quote
Last: | $1.845 |
---|---|
Change Percent: | -0.56% |
Open: | $1.79 |
Close: | $1.845 |
High: | $1.845 |
Low: | $1.7501 |
Volume: | 6,194 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.845 | $1.79 | $1.845 | $1.845 | $1.7501 | 6,194 | 04-24-2024 |
$1.78 | $1.7 | $1.78 | $1.84 | $1.66 | 18,275 | 04-23-2024 |
$1.695 | $1.77 | $1.695 | $1.78 | $1.685 | 18,019 | 04-22-2024 |
$1.82 | $1.79 | $1.82 | $1.89 | $1.77 | 22,557 | 04-19-2024 |
$1.77 | $1.7 | $1.77 | $1.775 | $1.7 | 17,984 | 04-18-2024 |
$1.7 | $1.72 | $1.7 | $1.7346 | $1.7 | 10,066 | 04-17-2024 |
$1.67 | $1.8 | $1.67 | $1.87 | $1.65 | 28,169 | 04-16-2024 |
$1.81 | $2.01 | $1.81 | $2.01 | $1.8 | 46,275 | 04-15-2024 |
$2 | $2.08 | $2 | $2.08 | $1.99 | 19,049 | 04-12-2024 |
$2.02 | $1.97 | $2.02 | $2.1 | $1.97 | 27,830 | 04-11-2024 |
$1.9711 | $1.96 | $1.9711 | $1.9951 | $1.94 | 9,315 | 04-10-2024 |
$1.96 | $2.1 | $1.96 | $2.1 | $1.94 | 25,200 | 04-09-2024 |
$2.0296 | $2.05 | $2.0296 | $2.08 | $1.9875 | 25,034 | 04-08-2024 |
$2 | $1.96 | $2 | $2.06 | $1.96 | 19,079 | 04-05-2024 |
$1.98 | $1.99 | $1.98 | $2.03 | $1.9063 | 18,757 | 04-04-2024 |
$1.9563 | $1.9 | $1.9563 | $2 | $1.88 | 21,558 | 04-03-2024 |
$1.9 | $1.95 | $1.9 | $1.98 | $1.83 | 49,790 | 04-02-2024 |
$1.89 | $1.97 | $1.89 | $2.032 | $1.88 | 20,484 | 04-01-2024 |
$1.86 | $1.97 | $1.86 | $1.97 | $1.8 | 70,723 | 03-29-2024 |
$1.86 | $1.97 | $1.86 | $1.97 | $1.8 | 70,723 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Sonnet BioTherapeutics Holdings Inc. Company Name:
SONN Stock Symbol:
NASDAQ Market:
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (rec...
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerability of SON-080 was consistent with data from previous IL-6 candidates, meeting the Phase...
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology . SON-1010, Sonnet's lea...